| Nov 4 |
Endeveco Bio spin-off to launch obesity trial
|
| Nov 4 |
Big Pharma’s Obesity Bonanza Faces New Tests
|
| Nov 4 |
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
|
| Nov 4 |
Novo Nordisk reports positive data from part one of semaglutide trial for MASH
|
| Nov 4 |
FTSE 100 LIVE: European markets mixed ahead of US election and UK interest rate decision
|
| Nov 3 |
What To Expect in the Markets This Week
|
| Nov 2 |
New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity
|
| Nov 2 |
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
|
| Nov 2 |
Novo Nordisk Reports Positive ESSENCE Trial Results
|
| Nov 1 |
Election Day, Fed decision, earnings: What to Watch Next Week
|
